Business
Regen BioPharma, Inc. Licenses NR2F6 Technology for Cancer Treatment and Autoimmune Disorders to CheckPoint Immunology Inc.
Regen BioPharma, Inc. Licenses NR2F6 Technology for Cancer Treatment and Autoimmune Disorders to CheckPoint Immunology Inc..
About this update from Regen Biopharma, Inc.
[{"type":"text","content":"\n\n\n\nRegen BioPharma, Inc. Licenses NR2F6 Technology for Cancer Treatment and Autoimmune Disorders to CheckPoint Immunology Inc.\n\n\n\n\n\nRegen BioPharma, Inc. Licenses NR2F6 Technology for Cancer Treatment and Autoimmune Disorders to CheckPoint Immunology Inc.\nPR Newswire\nSAN DIEGO, March 2, 2017\n\n\n\nSAN DIEGO, March 2, 2017 /PRNewswire/ --\n\nCheckPoint Formed as a Subsidiary of the Company to Simplify any Potential Future Transactions Involving the Company's NR2F6 Technology \n\nRegen BioPharma Inc. (OTCQB: RGBP), (OTCQB: RGBPP) has granted CheckPoint Immunology Inc. (a wholly-owned subsidiary of the Company) an exclusive worldwide license to develop and commercialize Regen's NR2F6 technology for human therapeutic use. The objective of the license grant is the separation of Regen's small molecule technology from its other intellectual property in order to facilitate any future transactions involving small molecule therapies focused on the NR2F6 checkpoint.\n\nThe Company's focus on NR2F6 has two developmental streams. The first area of development involves the inhibition of the checkpoint, NR2F6, in order to cause the body's immune system to destroy cancer cells. The second area of development involves the activation of NR2F6 which is believed to be a fulcrum for curing such autoimmune diseases as rheumatoid arthritis.\n\nRegen BioPharma's Chairman and CEO, David Koos, stated, \"In the beginning, Regen's business model was created with the goal of developing intellectual property to a point of attracting large pharmaceutical companies, to participate in maturing Company assets, either by sale, license or co-development. By forming CheckPoint Immunology, we are setting our game plan in place so that as we get further along in our development of small molecule therapies for treating cancer and autoimmune diseases, we can structure a transaction specific to NR2F6-related therapies. The Company has been approached by numerous parties interested in our NR2F6 based therapies. We expect, as we further optimize our small molecule compounds, there should be even greater interest. Hence the reason for creating CheckPoint Immunology is as a pure vehicle for any future NR2F6 transaction.\"\n\nDr. Harry Lander, Regen's president and CSO, noted, \"Biotechnology companies focused on successful immune-oncology therapies are ge...